Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 5;110(6):2318-23.
doi: 10.1073/pnas.1215498110. Epub 2013 Jan 23.

Hydrogel drug delivery system with predictable and tunable drug release and degradation rates

Gary W Ashley  1 , Jeff Henise, Ralph Reid, Daniel V Santi
Affiliations

Hydrogel drug delivery system with predictable and tunable drug release and degradation rates

Gary W Ashley et al. Proc Natl Acad Sci U S A. .

Abstract

Many drugs and drug candidates are suboptimal because of short duration of action. For example, peptides and proteins often have serum half-lives of only minutes to hours. One solution to this problem involves conjugation to circulating carriers, such as PEG, that retard kidney filtration and hence increase plasma half-life of the attached drug. We recently reported an approach to half-life extension that uses sets of self-cleaving linkers to attach drugs to macromolecular carriers. The linkers undergo β-eliminative cleavage to release the native drug with predictable half-lives ranging from a few hours to over 1 y; however, half-life extension becomes limited by the renal elimination rate of the circulating carrier. An approach to overcoming this constraint is to use noncirculating, biodegradable s.c. implants as drug carriers that are stable throughout the duration of drug release. Here, we use β-eliminative linkers to both tether drugs to and cross-link PEG hydrogels, and demonstrate tunable drug release and hydrogel erosion rates over a very wide range. By using one β-eliminative linker to tether a drug to the hydrogel, and another β-eliminative linker with a longer half-life to control polymer degradation, the system can be coordinated to release the drug before the gel undergoes complete erosion. The practical utility is illustrated by a PEG hydrogel-exenatide conjugate that should allow once-a-month administration, and results indicate that the technology may serve as a generic platform for tunable ultralong half-life extension of potent therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1.
Scheme 1.
Fig. 1.
Fig. 1.
Drug release from polymeric gels. (A) Encapsulated drug released concomitant with gel degradation. (B) Release by linker cleavage of covalently tethered drug, followed by gel degradation.
Scheme 2.
Scheme 2.
Fig. 2.
Fig. 2.
Idealized hydrogels formed from four-arm PEG azide and (A) four-arm PEG-CO (4 × 4 gel) or (B) eight-arm PEG-CO (4 × 8 gel) with four available cyclooctynes. Circles represent a drug or drug surrogate (D) tethered to the network by a releasable linker, or an erosion probe (EP) connected by a stable linker; L1 is a β-eliminative linker that releases the drug, and L2 is a β-eliminative cleavable cross-link of the gel.
Fig. 3.
Fig. 3.
Degradation of and drug release from hydrogels. (A) Degradation of PEG hydrogels at pH 7.4, 37 °C, as measured by solubilized PEG-fluorescein fragments. Reverse-gelation times using different modulators are ClPhSO2− = 30 h, PhSO2− = 55 h, O(CH2CH2)2NSO2− = 22 d, CN = 105 d; the lines connecting the points are a visual guide in observing the trends of the data. (B) Release of a drug surrogate, aminoacetyl-fluorescein (AAF), using β-eliminative linkers with varying cleavage t1/2 values. The lines show the best fit of the data to a first-order rate equation, and SEs were <4.2% of the rate constants (SI Text, Drug Release from β-Eliminative Linkers); tRGEL was 630 ± 39 (SD) h (n = 8), and observed t1/2 values for total drug release using different modulators were ClPhSO2− = 33 h, PhSO2− = 65 h, MeOPhSO2− = 131 h, and MeSO2− = 212 h.
Fig. 4.
Fig. 4.
Exenatide release from and erosion of hydrogel. Data obtained at pH 8.8 [k = 0.75 ± 0.057 (SE) d−1] was estimated at pH 7.4 using tpH7.4 = tpH8.8 × 10pH8.8–7.4 based on observations that β-eliminative cleavages are first-order in hydroxide ion for drug release (3) and gel degradation (Fig. S1); (–●–) Total exenatide released from gel (free and PEG fragments); (–■–) gel erosion. The line for exenatide release is the best exponential fit of the data, and the lines connecting the gel degradation points are a visual guide in observing the trends of the data.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Greenwald RB, et al. Controlled release of proteins from their poly(ethylene glycol) conjugates: Drug delivery systems employing 1,6-elimination. Bioconjug Chem. 2003;14(2):395–403. - PubMed
    1. Filpula D, Zhao H. Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev. 2008;60(1):29–49. - PubMed
    1. Santi DV, Schneider EL, Reid R, Robinson L, Ashley GW. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. Proc Natl Acad Sci USA. 2012;109(16):6211–6216. - PMC - PubMed
    1. Alconcel SNS, Baas AS, Maynard HD. FDA-approved poly(ethylene glycol)–protein conjugate drugs. Polym Chem. 2011;2(7):1442–1448.
    1. Fishburn CS. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10):4167–4183. - PubMed

MeSH terms

  NODES
admin 7
Idea 3
idea 3
innovation 1
twitter 2